CardioGenics Holdings Inc. is engaged in business of development of products targeting the immunoassay segment of the point-of-care in vitro diagnostic (IVD) testing market. The Company is engaged in development of technology and products, which include The QL Care Analyzer (QLCA), Cardiovascular Tests and Paramagnetic beads. The QLCA is a point-of-care (POC) immunoassay analyzer. The QLCA uses a self-metering cartridge to perform immunoassay tests at the POC. To support the use of the QLCA, the Company develops approximately four immunoassay tests designed to identify cardiac markers in the blood at the time of a heart attack. Its immunoassay tests include Troponin I (TnI), Plasminogen Activator Inhibitor Type-1 (PAI-1), Heart Failure Risk Stratification (HFRS) and Heart Failure Genomics Risk (HFGR). The Company's TnI test product is in the pilot testing phase. Paramagnetic (magnetic) beads are the solid phase employed during immunoassays tests.
|Headquarters||6865 SW 18th St Ste B13|
BOCA RATON, FL, United States 33433-7057
|Director/Acting Chairman||J. Tabatznik|
|Director & Chief Executive Officer||Yahia Gawad|
|Chief Financial Officer||James Essex|
|Corporate Secretary, Director||Linda Sterling|
|Independent Director||Karim Murabet|
|Shares Out.||96.1M||Book Value||$-0.01|
|CardioGenics Holdings Inc does not pay a dividend.||P/E||--|
|P/Cash Flow (TTM)||--|
*GAAP = prior to non-GAAP analyst adjusted earnings.